Platelet Enzymatically Oxidized Phospholipids (eoxPL) Characterisation in a Healthy Cohort on and Off Aspirin

Platelet Dysfunction Due to Aspirin Clinical Trial

Official title:

Platelet Enzymatically Oxidized Phospholipids (eoxPL) Characterisation in a Healthy Cohort on and Off Aspirin

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05604118
• Other study ID #: SMREC16/02
• Status: Completed
• Phase: N/A
• Start date: August 1, 2016
• Est. completion date: June 1, 2022

Study information

• Verified date: October 2022
• Source: Cardiff University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Healthy volunteers (n = 28) were recruited from the workplace (14 male, 14 female; age range 20-50 years). Ethical approval, which included informed consent, was from Cardiff University, Schools of Medicine and Dentistry Research Ethics Committee (SMREC16/02). Following a 2-week period free from non-steroidal anti-inflammatory drugs (NSAIDs), peripheral blood was obtained and platelets isolated. Participants were commenced on aspirin 75 mg once daily for seven days and then provided a repeat blood sample. Following a 2-month period, participants were invited to repeat samples pre- and post-aspirin, and again a third time 2 months later.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 28
• Est. completion date: June 1, 2022
• Est. primary completion date: August 1, 2018
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 20 Years to 50 Years

Eligibility

Inclusion Criteria:

• two-week washout period from any non-steroidal anti-inflammatory drugs (NSAIDs) use.

• Ability to take aspirin 75 mg once daily for seven days and sampled thereafter, before stopping the aspirin.

• Willingness to repeat this process after two months and four months of the initial sampling date.

Exclusion Criteria:

• Recent NSAID use

Related Conditions & MeSH terms

• Platelet Dysfunction Due to Aspirin

Intervention

Drug:
• Aspirin
1 week of aspirin supplementation prior to sampling

Locations

Country	Name	City	State
United Kingdom	Sir Geraint Evans Cardiovascular Research Building	Cardiff

Sponsors (1)

Lead Sponsor	Collaborator
Cardiff University

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Platelet EoxPL differences in amounts (ng) as measured by liquid chromatography with tandem mass spectrometry	Samples on and off aspirin will be quantified for the 47 most common eoxPL species (as described by Slatter et al, Cell Metabolism 23, 930-944, May 10, 2016) using established liquid chromatography with tandem mass spectrometry (LC-MS/MS). Differences in amounts on and off aspirin will be quantified and tested for statistical significance.	4 months